Weiss Healthcare announced that the cumulative deviation value of the closing price increase of the company's stock over three consecutive trading days exceeded 30%, which is an abnormal fluctuation in stock trading. After the company's own inspection, it was confirmed that there were no important matters relating to the company that should have been disclosed but not disclosed, and the company currently produces and operates normally. In the first three quarters of 2025, the company achieved operating income of 326 million yuan, an increase of 11.58% year on year; net profit attributable to shareholders of the parent company was 102 million yuan, an increase of 30.68% year on year. By the end of 2025, the company's new products in the field of brain-computer interfaces are still in the early stages of market development. The main layout is non-intrusive technology routes. There is a significant technical path difference with the current international leading intrusive brain-computer interface. Related products have not yet been sold on a large scale, and their contribution to overall revenue is still limited.

Weiss Healthcare announced that the cumulative deviation value of the closing price increase of the company's stock over three consecutive trading days exceeded 30%, which is an abnormal fluctuation in stock trading. After the company's own inspection, it was confirmed that there were no important matters relating to the company that should have been disclosed but not disclosed, and the company currently produces and operates normally. In the first three quarters of 2025, the company achieved operating income of 326 million yuan, an increase of 11.58% year on year; net profit attributable to shareholders of the parent company was 102 million yuan, an increase of 30.68% year on year. By the end of 2025, the company's new products in the field of brain-computer interfaces are still in the early stages of market development. The main layout is non-intrusive technology routes. There is a significant technical path difference with the current international leading intrusive brain-computer interface. Related products have not yet been sold on a large scale, and their contribution to overall revenue is still limited.